Georg Richtig

13PUBLICATIONS
26CO-AUTHORS
Molecular targetsReaction engineering (excl. nuclear reactions)Biological network analysisMedical infection agents (incl. prions)Te mātai tahumaero o te Māori (Māori epidemiology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 18, 2026
ROS1-Mutated Inoperable Spindle Cell Sarcoma Treated With Repotrectinib-A Case Report.

|Dec 21, 2023
New ways to strengthen old risk factors.

Georg Richtig, Erika Richtig

|Jul 07, 2023
Predatory journals: Perception, impact and use of Beall's list by the scientific community-A bibliometric big data study.

Georg Richtig, Marina Berger, Max Koeller

|Jan 16, 2023
Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma.

Lukas Buchacher, Georg Richtig, Marie Dernoscheg

|Aug 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.

Matthew Dankner, Yifan Wang, Rouhi Fazelzad

|Apr 26, 2022
Long-term adherence to melanoma follow-up examinations - a telephone survey.

L Buchacher, G Richtig, C Schöffl

Pageof 3

Frequent Collaborators

2 joint publications

Lukas Koch

1 joint publications

T Deinlein

1 joint publications

Gerald Hoefler

1 joint publications

Matthew Dankner